Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. [PDF]
Qual Life ResHuang Y, Chu Q, Wang J, Zhang L.
europepmc +1 more source
Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors. [PDF]
Front PharmacolGu J +5 more
europepmc +1 more source
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report. [PDF]
Lung Cancer (Auckl)Lee ATM +4 more
europepmc +1 more source
An updated review on systemic therapy for brain metastases in non-small cell lung cancer. [PDF]
Transl Cancer ResLouis S +4 more
europepmc +1 more source
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review. [PDF]
Curr OncolBischoff H +4 more
europepmc +1 more source
Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer. [PDF]
Transl Lung Cancer ResMorise M, Tanaka I, Ishii M.
europepmc +1 more source
Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape. [PDF]
Transl Lung Cancer ResKatayama Y.
europepmc +1 more source
Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report. [PDF]
Front OncolLin M, Gao Y, Deng J.
europepmc +1 more source
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. [PDF]
J Manag Care Spec PharmMudumba R +4 more
europepmc +1 more source
Lung adenocarcinoma with <i>ALK</i> deletion of exons 6-20 with response to sequential ALK inhibitors: a case report. [PDF]
Transl Lung Cancer ResJinno K +7 more
europepmc +1 more source